A phase I clinical trial to evaluate the safety and immunogenicity of a clade B Gag DNA/PLG and Env DNA/PLG microparticles vaccine and a Clade B recombinant, oligomeric gp140/MF59 adjuvant vaccine in healthy, HIV-1 uninfected adult participants.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HIV DNA vaccine; HIV vaccine; MF 59
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 04 May 2012 Biomarkers information updated
- 03 May 2012 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
- 01 Apr 2011 Results published in the Journal of Infectious Diseases.